Introduction
The World Health Organization (WHO) has stated that tuberculosis (TB) and human immunodeficiency virus (HIV) infections will be among the top 20 causes of death up to 2030. 1 Both are chronic infectious diseases that mainly affect the most disadvantaged populations, involve complex treatment regimens with potentially severe side effects, and are frequently associated with non-adherence to treatment, which may result in drug resistance. 2, 3 According to Bangsberg et al, adherent patients have a longer period of successful treatment and also have lower mortality rates than patients who are less adherent in urban settings of San Francisco. 4 Access to anti-TB treatment and to antiretroviral (ARV) medication has become more widely available. For Corless et al, the question remains as to how to maintain high adherence with respect to ARV treatment in the context of lack of food and other basic necessities in Durban, South Africa 5 ; in the context where interrupted treatment may reduce treatment efficacy and cause drug resistance, it can result in increased morbidity and mortality as well as additional infections. 6 It is known that adherence rates to long-term medication in high income countries have been estimated to be only 50%, whereas adherence in developing countries seems to be even lower. 2 Therefore, adherence of TB and HIV/AIDS patients to treatment remains a challenge. An important difference in medication adherence between TB and HIV patients is that TB patients only need to take 6e9 months of medication and HIV patients need lifelong treatment. Additionally, some factors have not been considered in previous studies: ever been lost to follow-up, duration of residence, number of persons sleeping in the household, first choice for consultation for the disease, awareness of disease transmission, and psychosocial consequences of the disease. Using a large range of variables, the present study aims to identify potential determinants of medication adherence among patients with TB, HIV, and patients coinfected with TB and HIV in a developing country, Burkina Faso.
Methods

Study type and setting
This cross-sectional study uses a survey conducted in health centers and non-governmental organizations (NGOs) located in the Centre and Hauts-Bassins regions of Burkina Faso. These two regions harbor approximately 40% of the TB cases nationwide, have the highest HIV prevalence, and have the largest number of NGOs providing ARV treatment in the country.
In the Centre region, TB patients were identified from data provided by the National TB Diagnosis, Treatment and Research Centre, and five Health Districts (HDs), namely Boulmiougou, Baskuy, Sig-Noghin, Bogodogo, and NongrMassom. In the Hauts-Bassins region, TB patients were identified from data provided by the Regional TB Diagnosis and Treatment Centre (TDTC), Souro Sanou National Teaching Hospital (NTH), and six HDs, namely Orodara, Do, Dafra, Lena, Houndé, and Karangasso-Vigué. In total, 309 incident TB cases and 52 prevalent TB cases participated in this study.
HIV patients were identified from data provided by various NGOs and HDs, which were the same as those for TB patients. The NGOs were the Association-Espoir-Vie (AES) and Responsabilité-Espoir-Vie-Solidarité (REVSþ) from Bobo Dioulasso in the Hauts-Bassins region; and the Association des Jeunes pour la Promotion des Orphelins (AJPO) from Ouagadougou in the Centre region.
Sample size calculation
Sample size was calculated using the online sample size calculation provided by RASOFT. 7 A common margin of error of 5% was used. Thus, a confidence level of 95% was chosen, with a response distribution of 50%, a power equal to 80%, and assuming a normal distribution. With the knowledge that the total number of TB cases for both regions was 1832 in 2008, 8, 9 the minimal TB sample size expected was 316 cases for the two regions. In addition, in terms of HIV sample size, the normal rule of having one case for at least two controls was applied; thus, at least 600 HIV cases were needed.
Study planning, research approval, and recruitment of patients
The study was conducted from 1 August to 8 October, 2010 after advice and guidance was obtained from the National Yang-Ming University of Taipei (Taiwan) and from the National TB program of Burkina Faso, together with an expert opinion from the West African Health Organization. The study was approved by the Research Ethics Committee of Burkina Faso and the Ministry of Health in July 2010. With these approvals, we obtained administrative support that facilitated carrying out the study in the various health regions and districts within the Centre and Hauts-Bassins regions.
This study used a consecutive patient method. The inclusion criteria were filled when the patient was a confirmed TB case from a TB clinic and was undergoing anti-TB treatment. Similar criteria were used for HIV cases from AIDS clinics under highly active antiretroviral therapy (HAART). In addition, the patient was required to be 15 years and older, and living in the study setting. Both sexes were included.
Formative research and data collection
After obtaining informed consent from each patient, a face-to-face interview was conducted using a semistructured questionnaire consisting of two parts. The first part recorded the individual's clinical information and comorbidities (10e15 minutes) and was completed during the interview. The remaining section of the questionnaire needed 25e30 minutes to be completed.
The independent variables were sociodemographic and economic status (age, sex, area, region, education level, religion, profession, monthly income, means of transportation, adapted self-esteem (eight-item scale, with Cronbach's a Z 0.873), 10 adapted quality of life from the WHO quality of life (feelings about life, capability, and expectations for the future, with an eight-item scale, Cronbach's a Z 0.726), 11 adapted knowledge index about TB, 12 adapted attitude index, 12 adapted perception index (discrimination and isolation), 13 awareness of disease transmission (three-item scale, Cronbach's a Z 0.783).
Medication adherence was measured using the Morisky scale (eight-item scale, Cronbach's a Z 0.711).
14 It is a validated and qualified scale which is an indirect method for evaluating medication with behavior using a self-report and patient behavior in the context of chronic diseases. In this regard, we minimized the effect linked to the duration of treatment in different patients at different stages and avoided the effect of insufficient managing by medical charts. We referred only to anti-TB and ARV treatments according to the context in Burkina Faso: the drugs for prevention were not systematically used. The sum of medication adherence index ranged from zero (lowest) to eight (highest). Predictors of good adherence were defined as those that were positively correlated with medication adherence, whereas poor predictors were defined as those that were negatively correlated with medication adherence. In addition to collecting psychosocial and behavioral information from patients, data were also collected on present or past clinical information (CD4 cell count, diabetes, cardiovascular disease, arterial hypertension, and pulmonary asthma), health system-related factors (financial and geographical access, work force perceived by patients, waiting time of consultation), first place of consultation (when sick, for present disease, and when having cough), duration of residence, past history of TB, having ever been lost to follow-up, comorbidities [smoking, alcoholism, prisoner status, knowledge of viral hepatitis B and C, sexually transmitted infections (STIs), and injection drug use (IDU)], psychosocial consequences of the disease, type of alimentation, and sexual orientation. Before conducting the final survey, the questionnaire underwent pretesting in order to reduce bias and to better control the time needed for completing the questionnaire.
HIV testing and TB confirmation
HIV status and TB status were confirmed from the medical and biological records of each patient. In TB patients, TB smear result was considered positive when at least two sputum samples of the patient were examined and the germ of the TB disease was detected by light microscopy after Ziehl-Neelsen staining. In HIV patients, a HIV test was positive when antibodies were detected by an initial test based on the ELISA method, and then confirmed by a second test using the Western blot procedure.
Data analysis
Data were entered into EPIDATA (3.0 Software, EpiData Association, Odense, Denmark) and analyzed by the SPSS PC statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA). The cut-off point for continuous variables was the median. The level of significance was 0.05. A comparison of the variables between patients with TB, HIV, and both was carried out using the Chi-square test for categorical data and a two-sample t test or F test for continuous data.
Simple and multiple stepwise linear regression models were then used to identify predictors of the medication adherence index. Only significant predictor factors of medication adherence at the univariate analysis were entered into the model for multivariate analysis.
Results
Participants and sample characteristics
There were 1290 patients who met the inclusion criteria during data collection (Fig. 1) . After eligibility and enrollment, the sample size under study was reduced to 1043 participants out of which 605 patients were from HIV clinics (from public sector and NGOs, and 52 were coinfected with TB and HIV) and 438 from TB clinics (all from public sector, and 129 were coinfected with TB and HIV). The non-eligible cases were those who refused to respond to the questions and the questionnaire (n Z 69), HIV patients who were not under ARV treatment (n Z 20), and those who responded but provided incomplete information (n Z 58). This final sample of 1043 patients consisted of 309 TB patients, 553 HIV/AIDS cases, and 181 patients coinfected with TB and HIV. All patients were heterosexual and ate mixed food.
Factors that differ among TB infected, HIV infected, and TB/HIV coinfected patients There were no differences among patients with TB, HIV, and TB/HIV coinfection in alcohol status, waiting time perceived by patients, patient status (TB infected and HIV infected versus coinfected with TB and HIV), ever been lost to follow-up, IDU, place for consultation when sick and having a cough, and past/present disease history.
Predictors of medication adherence index
Univariate analysis predictors for medication adherence were patient status (TB and HIV infection versus coinfection with TB and HIV), alcohol status, IDU, ever been lost to follow-up, first choice for consultation, waiting time perceived by patients, number of persons sleeping in the household, attitudes, financial access to care, perceived work force, self-esteem, stigma, discrimination isolation, awareness of disease transmission, and knowledge about TB transmission (Tables 1e3) . Sociodemographic variables were not predictor factors of medication adherence. From the pooled data, adjusted predictors of good medication adherence were no alcohol use, ever been lost to follow-up, first place consultation for present disease, financial access to care, perceived work force, less stigma, and awareness of disease transmission (Tables 1e3). Furthermore, adjusted predictors of poor medication adherence were high number of persons sleeping in the household and consulting healer for present disease. Patient status was not found to be predictive of medication taking behavior [b: 0.146 (À0.119 to 0.411)].
In TB patients (Table 1) , the adjusted predictors of good medication adherence were no alcohol use, ever been lost to follow-up, and awareness of disease transmission. Poor financial access to care was an adjusted predictor of poor medication adherence.
In HIV/AIDS patients (Table 4) , the adjusted predictors of good medication adherence were fewer stigmata, good knowledge about TB transmission, and high awareness of disease transmission.
In patients coinfected with TB and HIV (Table 4) , good attitude was an adjusted predictor of good medication adherence, whereas high number of persons sleeping in the household was an adjusted predictor of poor medication adherence. 
Discussion
This cross-sectional study was conducted via TB and HIV clinics using health centers and NGOs of two main regions (Centre and Hauts-Bassins) in Burkina Faso (Table 5) . Our objective was to identify predictors of the medication adherence index among TB infected, HIV infected, and TB/ HIV coinfected patients in Burkina Faso. This study exhaustively explored a wide range of variables using faceto-face interviews and semi-structured questions in order to construct strong scales and indices. Nonetheless, the present study may be criticized because it is crosssectional. Furthermore, some factors explored in the literature were not analyzed in the present study because the records from the TB and HIV clinics were not identical and because they had not been systematically collected as part of the patients' medical records. These included clinical forms of TB or HIV, 15, 16 hemoglobin level, 16 plasma viral load, 15,17,18 and undernutrition. 19e21 Because this study identified many variables associated with medical adherence, further evaluation of their interactions may be needed in the future.
The present study found significant differences between socioeconomic and psychosocial variables among TB infected, HIV infected, and TB/HIV coinfected patients. This was in agreement with the findings of a South African study, in which the authors concluded that HIV and TB cohorts had distinct socioeconomic and psychosocial backgrounds. 5 The results showed that total TB knowledge was significantly and positively correlated with medication adherence in the pooled data (p Z 0.005) and in HIV patients (p Z 0.001) at the univariate stage and in HIV patients (p Z 0.048) at the multivariate analysis stage. This could be explained by information received regularly by HIV patients during group discussions, counseling, and consultations. A study by Kalichman et al showed that the ability of patients to understand both their disease and its treatment had a major effect on adherence. 22 According to Okanurak et al, a patient's knowledge level of TB and its treatment contributed to treatment success in Bangkok. 23 In Nepal, non-adherent patients cited insufficient knowledge about the need to take daily treatment, especially after they felt better, as a reason affecting patient adherence to directly observed treatment, short course (DOTS). 24 Kaona et al reported that non-compliance was associated with a lack of knowledge of the benefits of completing a course, with running out of drugs at home and with the TB drugs being "too strong" to continue. 25 Thompson et al stated that improving patients' knowledge and understanding of their disease and its treatment, either via nursing staff or via community-led pharmacies, had a positive impact on adherence levels. 26 In addition to TB knowledge as adjusted predictor factor for medication adherence, the present study found that predictors for medication adherence were alcohol use, attitude towards TB and HIV, awareness of disease transmission, financial access to care, and high number of persons sleeping in the household. At the univariate analysis stage, Shin et al found low social support, substance use, and depression to be associated with non-adherence. 27 Corless et al reported that treatment failure was related to inappropriate regimens, the unavailability of drugs, or lack of access to health care. 20 Sabaté suggested that treatment adherence was also affected by beliefs about the origins, transmission, and treatment of TB and HIV, which often resulted in the stigmatization of those affected. 2 Several questionnaires on behavior have identified psychological determinants that seem to be factors associated with a predisposition towards non-adherence. 18 Moreover, in a multivariable analysis, Shin et al found that low social support was associated with non-adherence. 27 In contrast to the findings of a literature review, the present study identified other adjusted predictors such as having ever been lost to follow-up and number of persons sleeping in the household. For patients with TB, ever been lost to follow-up was a predictor of good medication adherence. Because this was a cross-sectional study and only enrolled persons returned for treatment, there may be a loss to follow-up bias. Another explanation is that because they returned for treatment, they had fewer problems with complex treatment (ARV or anti-TB). In addition, this may be explained by the Morisky scale questions.
The present study showed the necessity to consider different profiles of patients inside TB and HIV control programs. Indeed, for different patient profiles (TB, HIV, and TB/HIV coinfection), the study identified different predicting factors of medication adherence. These factors should be taken into consideration when designing and implementing projects and programs for TB and HIV.
In conclusion, this study provides information on medication adherence in TB infected, HIV infected, and TB/HIV coinfected patients. The identified factors are important considerations that need to be incorporated into TB and HIV programs. Factors that have to be carefully considered in TB and HIV programs include stigma, attitude, status of loss to follow-up, TB knowledge, financial access to care, alcohol use, awareness of disease transmission, number of persons sleeping in the household. TB programs can be tailored to address each of these concerns in order to develop educational approaches for specific groups. 28 The factors identified in this study need to be taken into account during the sensitization, project planning, and research stages.
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